About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Tennessee | 20,239 Studies Near You | Clareo Health

Clinical Trials LocationsTennessee

Clinical Trials in Tennessee

Discover 20,239 clinical trials near Tennessee. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 13321-13340 of 20,239 trials

COMPLETEDNA29 miles

Aortic Valve Replacement With Trifecta(TM)

NCT00475709

To confirm the clinical safety and effectiveness of the Trifecta valve.

Aortic Valve InsufficiencyRegurgitation, Aortic ValveAortic Valve Incompetence+1 more

Abbott Medical Devices1,022 participantsStarted Jun 2007

Los Angeles, California, United States • Sarasota, Florida, United States • Maywood, Illinois, United States +15 more locations

COMPLETEDNA29 miles

Detect Fluid Early From Intra-thoracic Impedance Monitoring

NCT00916929

To demonstrate the safety and effectiveness of the Impedance Monitoring Feature in St Jude Medical cardiac devices.

Abbott Medical Devices162 participantsStarted May 2009

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Little Rock, Arkansas, United States +31 more locations

Find Trials by Condition in Tennessee

Breast Cancerin Tennessee Lung Cancerin Tennessee Prostate Cancerin Tennessee Colorectal Cancerin Tennessee Melanomain Tennessee Leukemiain Tennessee Lymphomain Tennessee Pancreatic Cancerin Tennessee Ovarian Cancerin Tennessee Brain Cancerin Tennessee

Data from ClinicalTrials.govTerms

TERMINATEDPhase 329 miles

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

NCT02815293

The objectives of this study are twofold * To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE) * To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice daily in patients with EDE

Dry Eye Syndromes

Allergan36 participantsStarted Sep 2016

Chandler, Arizona, United States • Fullerton, California, United States • Garden Grove, California, United States +26 more locations

TERMINATEDPhase 229 miles

GSK1120212 Rollover Study

NCT01376310

This was an open-label study to permit subjects with solid tumors or leukemia, who were clinically benefitting on another GSK sponsored trial with GSK1120212 either monotherapy or in combination continued access to GSK1120212.

Novartis Pharmaceuticals159 participantsStarted Nov 2010

Goodyear, Arizona, United States • Scottsdale, Arizona, United States • Sacramento, California, United States +16 more locations

COMPLETEDNA29 miles

Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds

NCT00746356

This study is a prospective, non-randomized, multi-center clinical trial that will assess the safety and effectiveness of investigational models of the Promote™ RF CRT-D and Current™ RF ICD devices. These new ICD and CRT-D devices have new features that allow the device to periodically check how much energy is needed to pace a patient's heart and to automatically adjust the amount of energy used to pace the heart.

Heart FailureVentricular Arrythmias

Abbott Medical Devices128 participantsStarted Aug 2008

Little Rock, Arkansas, United States • Little Rock, Arkansas, United States • Browns Mills, New Jersey, United States +2 more locations

COMPLETEDNA29 miles

Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial

NCT00465270

The purpose of this study is to investigate whether percutaneous Patent Foramen Ovale (PFO) closure, using the AMPLATZER PFO Occluder, is superior to current standard of care medical treatment in the prevention of recurrent embolic stroke.

Cryptogenic Stroke

Abbott Medical Devices980 participantsStarted Aug 2003

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +66 more locations

COMPLETEDPhase 329 miles

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

NCT02320149

To evaluate the efficacy and safety of an approximate 1.5mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

Almirall, S.A.968 participantsStarted Dec 2014

Beverly Hills, California, United States • Encino, California, United States • La Mesa, California, United States +54 more locations

COMPLETEDPhase 373 miles

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

NCT01523587

This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.

Carcinoma, Non-Small-Cell Lung

Boehringer Ingelheim795 participantsStarted Mar 2012

Chandler, Arizona, United States • La Jolla, California, United States • Sacramento, California, United States +189 more locations

COMPLETEDNA154 miles

Veterans Individual Placement and Support Towards Advancing Recovery

NCT01817712

The primary objective of CSP#589 VIP-STAR is to evaluate the effectiveness of Individual Placement \& Support (IPS) in unemployed Veterans with PTSD. The primary hypothesis is that, compared to those treated with transitional work program (TWP), unemployed Veterans with PTSD treated with IPS will be significantly more likely to become a steady worker. A steady worker is defined as holding a competitive job for greater than or equal to 50% of the 18-month study follow-up period (i.e., greater than or equal to 39 of the 78 weeks). All participants will be followed for 18 months post-randomization. 12/14/12: Analytic plan augmented to allow for a sensitivity analysis of the primary outcome that would exclude the first 12 weeks post-randomization, and evaluate between group proportion of steady worker status, as defined by working in a competitive job for greater than or equal to 50% of the weeks during week 13-78. 7/1/13: Analysis plan has been augmented to include a logistic regression analysis of the primary outcome, adjusted for participating medical center. 10/4/13: Addition of the IPS-25 Fidelity Scale. The addition of the IPS-25 scale should increase the validity of study results. 1/15/15: Addition of an Interactive Voice Recognition/Web-based (IVR/Web) System; as an option for weekly data capture of the primary outcome data (employment history). 8/17/15: Approval of Supplemental Data Collection at Participant Study Exit; use of the data collected will supplement the study analysis plan and, provide further insight into the impact of vocational rehab. A Participant Satisfaction Survey will allow study participants to indicate their level of satisfaction with the study, vocational rehabilitation intervention and, suggestions for future research.

Posttraumatic Stress Disorder (PTSD)

VA Office of Research and Development541 participantsStarted Dec 2013

Birmingham, Alabama, United States • Tuscaloosa, Alabama, United States • San Francisco, California, United States +10 more locations

COMPLETEDNA154 miles

eHealth Partnered Evaluation Initiative

NCT02665468

On October 1, 2016, the VHA Office of Telehealth and the Connected Health Office will merge to create a single entity that will be responsible for the implementation and evaluation of eHealth technologies across the healthcare system. In an effort to successfully fulfill its mission, the new combined Connected Health/Telehealth Office is pledging $1,100,000 for an eHealth Partnered Evaluation Initiative (PEI) to support the further implementation of eHealth technologies across VHA, and to measure their impacts on dimensions of access and other outcomes. Developed in close consultation with leadership of the new office, the proposed objectives of the eHealth PEI are to (1) implement a patient-level "supported adoption intervention" for secure messaging and evaluate the impact of secure messaging use through a rapid, one-year randomized trial; and (2) evaluate the initial rollout of VHA's automated telehealth text messaging system to Veterans and clinical team members.

Non-secure Message Senders

VA Office of Research and Development1,196 participantsStarted Feb 2016

Birmingham, Alabama, United States • Bedford, Massachusetts, United States • Pittsburgh, Pennsylvania, United States +1 more locations

COMPLETED154 miles

Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry

NCT00833170

The purpose of the Pediatric Inflammatory Bowel Disease Collaborative Research Group Registry is to study the contemporary natural history of children \<16 years of age newly diagnosed with inflammatory bowel disease. The project follows these children quarterly from diagnosis examining clinical, laboratory, and humanistic outcomes. Genetic and serologic monitoring is performed on the study population.

Inflammatory Bowel Disease

Connecticut Children's Medical Center1,600 participantsStarted Jan 2002

Birmingham, Alabama, United States • Hartford, Connecticut, United States • Washington D.C., District of Columbia, United States +25 more locations

COMPLETEDPhase 1174 miles

Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients

NCT00728936

First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.

Idera Pharmaceuticals, Inc.58 participantsStarted Sep 2007

Aurora, Colorado, United States • Marietta, Georgia, United States • Novi, Michigan, United States +4 more locations

COMPLETEDPhase 3190 miles

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure

NCT01471028

The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect to overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liver decompensation (AILD) up to at least Study Day 91, with follow-up Protocol VTI-208E providing additional survival data up to a maximum of 5 years that will be included, as available, through VTI-208 study termination (after the last surviving enrolled subject completes Study Day 91). Secondary objectives are to determine the proportion of survivors at Study Days 28 and 91. Exploratory objectives are to evaluate the ability of ELAD to stabilize liver function, measured using the Model for End Stage Liver Disease (MELD)-based time to progression (TTP) up to Study Day 91, and the proportion of progression-free survivors (PFS) up to Study Days 28 and 91. Progression is defined as death or the first observed increase of at least 5 points from End of Study Day 1 MELD score (for both the ELAD and Control groups) until at least 24 hours after the ELAD Treatment Period is ended (end of Day 7 for Controls) and up to both End of Study Days 28 and 91 following Randomization.

Acute Alcoholic Hepatitis

Vital Therapies, Inc.203 participantsStarted Feb 2013

Phoenix, Arizona, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +42 more locations

TERMINATEDNA232 miles

CONcomitant eValuation of Epicor Left atRial Therapy for AF

NCT00519194

The purpose of this study is to test the safety and efficacy of the Epicor LP Cardiac Ablation System for treating permanent atrial fibrillation during concomitant open chest and/or open heart surgery for one of more of the following procedures: mitral valve repair or replacement, aortic valve repair or replacement, tricuspid valve repair or replacement, coronary artery bypass surgery or patent foramen ovale (PFO closure).

Atrial Fibrillation

Abbott Medical Devices112 participantsStarted Apr 2009

Fresno, California, United States • Bradenton, Florida, United States • Bradenton, Florida, United States +12 more locations

TERMINATEDPhase 2277 miles

A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

NCT02731690

The primary objective of this Phase 2 study is to evaluate the safety of open-label 6 g/day Ace-ER in GNEM participants with severe ambulatory impairment.

Hereditary Inclusion Body MyopathyDistal Myopathy With Rimmed VacuolesDistal Myopathy, Nonaka Type+3 more

Ultragenyx Pharmaceutical Inc42 participantsStarted Apr 2016

Orange, California, United States • St Louis, Missouri, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 1279 miles

A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

NCT01094288

The purpose of this study is to evaluate the safety and tolerability of alisertib in combination with docetaxel as a treatment for participants with advanced solid tumors, including castration-resistant prostate cancer, who were deemed by the investigator to be medically appropriate candidates for docetaxel therapy.

Advanced Solid TumorsAdenocarcinoma of the Prostate

Millennium Pharmaceuticals, Inc.41 participantsStarted Aug 2010

Indianapolis, Indiana, United States • Portland, Oregon, United States • San Antonio, Texas, United States +1 more locations

COMPLETEDNA354 miles

FREEDOM - A Frequent Optimization Study Using the QuickOpt Method

NCT00418314

The objective of this study is to demonstrate that frequent atrio-ventricular (AV/PV) and inter-ventricular (V-V) delay optimization using QuickOpt in patients with cardiac resynchronization therapy device results in improved clinical response over standard of care (i.e. empiric programming or one-time optimization using any non-intracardiac electrogram optimization methods).

Cardiac ArrhythmiasHeart Failure

Abbott Medical Devices1,647 participantsStarted Oct 2006

Los Angeles, California, United States • Columbus, Ohio, United States

UNKNOWNNA465 miles

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

NCT03504761

The purpose of this study is to demonstrate the effectiveness and safety of the ClariCore System in obtaining prostate biopsies with device feedback that provides real-time tissue classification.

Cellular Diagnosis, Prostate Cancer

Precision Biopsy, Inc.325 participantsStarted Apr 2018

Denver, Colorado, United States • Baltimore, Maryland, United States • New York, New York, United States +3 more locations

UNKNOWNNA465 miles

ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy

NCT02928640

The purpose of the study is to collect information on prostrate biopsy tissue for use in developing a method determining the difference in normal and cancerous prostrate tissue using the ClariCore System.

Cellular Diagnosis, Prostate Cancer

Precision Biopsy, Inc.200 participantsStarted Sep 2016

Denver, Colorado, United States • Baltimore, Maryland, United States • Royal Oak, Michigan, United States +2 more locations

TERMINATEDPhase 2494 miles

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

NCT00917293

The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.

Tardive Dyskinesia

Medicure53 participantsStarted May 2009

Victoria, British Columbia, Canada • Toronto, Ontario, Canada • Windsor, Ontario, Canada +1 more locations

PreviousPage 667 of 1012Next

Diabetes

in Tennessee

Heart Diseasein Tennessee